PRESS RELEASE Statement attributable to:Andrew W.


Kaiser Family members Foundation. Kaiser Health Information, an editorially independent news service, is an application of the Kaiser Family Foundation, a nonpartisan health care policy research corporation unaffiliated with Kaiser Permanente.. PRESS RELEASE Statement attributable to:Andrew W. Gurman, M.D., President-elect, American Medical Association Within the AMA’s long-standing dedication to improving the health of the nation, we continue to focus our initiatives on identifying the very best ways to avoid the chronic diseases that have the biggest effect on public health and put a fiscal strain on our health and wellness care system. We are pleased to be taking part in the White Home Conference on Ageing and applaud the Administration for taking a step in the proper direction to bring even more attention to the importance of disease prevention, especially considering that more adults than ever before are living with multiple chronic conditions right now.Under the terms of the contract, Allergan will acquire AqueSys for a $300 million upfront payment and regulatory approval and commercialization milestone payments related to AqueSys' lead development applications, including XEN45. ‘The acquisition of AqueSys and its own XEN45 plan builds on Allergan's long-standing and deep dedication to innovation in eyesight care,’ said Brent Saunders, CEO and President of Allergan. ‘Our eye care team includes a strong track record of introducing novel remedies for sufferers with glaucoma. The acquisition of the XEN45 device demonstrates our dedication to alternative next-generation glaucoma remedies which are attractive to both sufferers and doctors and extend beyond regular medication eyedrops.’ The acquisition of AqueSys adds XEN45, a soft shunt that’s implanted in the subconjunctival space in the attention through a minimally invasive method with a single use, pre-loaded proprietary injector.